Retraction Note: Cannabinoid type 1 receptor availability in the amygdala mediates threat processing in trauma survivors (Neuropsychopharmacology, (2014), 39, 11, (2519-2528), 10.1038/npp.2014.110);Cannabinoid type 1 receptor availability in the amygdala mediates threat processing in trauma survivors

Neuropsychopharmacology

Volumn 39, Issue 11, 2014, Pages 2519-2528

  Pietrzak, Robert H ^a,b   Huang, Yiyun ^b   Corsi Travali, Stefani ^c   Zheng, Ming Qiang ^b   Lin, Shu Fei ^b   Henry, Shannan ^b   Potenza, Marc N ^b   Piomelli, Daniele ^d   Carson, Richard E ^b   Neumeister, Alexander ^c  

^a VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIDE; ANANDAMIDE; ARACHIDONIC ACID DERIVATIVE; CANNABINOID 1 RECEPTOR; CARBON; ENDOCANNABINOID; RADIOPHARMACEUTICAL AGENT;

ADULT; AMYGDALOID NUCLEUS; ATTENTION; BLOOD; FEAR; FEMALE; HUMAN; MALE; METABOLISM; MIDDLE AGED; NEUROPSYCHOLOGICAL TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; PSYCHOLOGIC TEST; SCINTISCANNING; YOUNG ADULT;

ADULT; AMYGDALA; ARACHIDONIC ACIDS; ATTENTION; CARBON RADIOISOTOPES; ENDOCANNABINOIDS; FEAR; FEMALE; HUMANS; INTERVIEW, PSYCHOLOGICAL; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; POLYUNSATURATED ALKAMIDES; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RECEPTOR, CANNABINOID, CB1; YOUNG ADULT;

EID: 84939881846     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/s41386-020-00818-1     Document Type: Erratum

References (61)

1. Ahn K, McKinney MK, Cravatt BF (2008). Enzymatic pathways that regulate endocannabinoid signaling in the nervous system. Chem Rev 108: 1687-1707.
2. Bar-Haim Y, Lamy D, Pergamin L, Bakermans-Kranenburg MJ, van IMH (2007). Threat-related attentional bias in anxious and nonanxious individuals: a meta-analytic study. Psychol Bull 133: 1-24.
3. Blankman JL, Cravatt BF (2013). Chemical probes of endocannabinoid metabolism. Pharmacol Rev 65: 849-871.
4. Bosier B, Muccioli GG, Hermans E, Lambert DM (2010). Functionally selective cannabinoid receptor signalling: therapeutic implications and opportunities. Biochem Pharmacol 80: 1-12.
5. Cadas H, Gaillet S, Beltramo M, Venance L, Piomelli D (1996). Biosynthesis of an endogenous cannabinoid precursor in neurons and its control by calcium and cAMP. J Neurosci 16: 3934-3942.
6. Carson RE Barker WC Liow J-S Adler S Johnson CA (eds) (2003). Design of a Motion-Compensation OSEM List-Mode Algorithm for Resolution-Recovery Reconstruction of the HRRT. Conf Record IEEE Nuclear Science Symposium and Medical Imaging Portland, OR.
7. Ceccarini J, Hompes T, Verhaeghen A, Casteels C, Peuskens H, Bormans G et al (2014). Changes in cerebral CB1 receptor availability after acute and chronic alcohol abuse and monitored abstinence. J Neurosc 34: 2822-2831.
8. Chiang KP, Gerber AL, Sipe JC, Cravatt BF (2004). Reduced cellular expression and activity of the P129T mutant of human fatty acid amide hydrolase: evidence for a link between defects in the endocannabinoid system and problem drug use. Hum Mol Genet 13: 2113-2119.
9. Cuthbert BN (2014). The RDoC framework: facilitating transition from ICD/DSM to dimensional approaches that integrate neuroscience and psychopathology. World Psychiatry 13: 28-35.
10. Di S, Malcher-Lopes R, Halmos KC, Tasker JG (2003). Nongenomic glucocorticoid inhibition via endocannabinoid release in the hypothalamus: a fast feedback mechanism. J Neurosci 23: 4850-4857.
11. El Khoury-Malhame M, Reynaud E, Soriano A, Michael K, Salgado-Pineda P, Zendjidjian X et al (2011). Amygdala activity correlates with attentional bias in PTSD. Neuropsychologia 49: 1969-1973.
12. Fani N, Jovanovic T, Ely TD, Bradley B, Gutman D, Tone EB et al (2012a). Neural correlates of attention bias to threat in posttraumatic stress disorder. Biol Psychol 90: 134-142.
13. Fani N, Tone EB, Phifer J, Norrholm SD, Bradley B, Ressler KJ et al (2012b). Attention bias toward threat is associated with exaggerated fear expression and impaired extinction in PTSD. Psychol Med 42: 533-543.
14. Forbes D, Lockwood E, Elhai JD, Creamer M, O'Donnell M, Bryant R et al (2011). An examination of the structure of posttraumatic stress disorder in relation to the anxiety and depressive disorders. J Affect Disord 132: 165-172.
15. Forbes D, Parslow R, Creamer M, O'Donnell M, Bryant R, McFarlane A et al (2010). A longitudinal analysis of posttraumatic stress disorder symptoms and their relationship with fear and anxious-misery disorders: implications for DSM-V. J Affect Disord 127: 147-152.
16. Glass M, Dragunow M, Faull RL (1997a). Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience 77: 299-318.
17. Glass M, Felder CC (1997b). Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors augments cAMP accumulation in striatal neurons: evidence for a Gs linkage to the CB1 receptor. J Neurosci 17: 5327-5333.
18. Grant DM, Beck JG, Marques L, Palyo SA, Clapp JD (2008). The structure of distress following trauma: posttraumatic stress disorder, major depressive disorder, and generalized anxiety disorder. J Abnorm Psychol 117: 662-672.
19. Gunduz-Cinar O, Hill MN, McEwen BS, Holmes A (2013a). Amygdala FAAH and anandamide: mediating protection and recovery from stress. Trends Pharmacol Sci 34: 637-644.
20. Gunduz-Cinar O, MacPherson KP, Cinar R, Gamble-George J, Sugden K, Williams B et al (2013b). Convergent translational evidence of a role for anandamide in amygdala-mediated fear extinction, threat processing and stress-reactivity. Mol Psychiatry 18: 813-823.
21. Hariri AR, Gorka A, Hyde LW, Kimak M, Halder I, Ducci F et al (2009). Divergent effects of genetic variation in endocannabinoid signaling on human threat- and reward-related brain function. Biol Psychiatry 66: 9-16.
22. Herkenham M (1991). Characterization and localization of cannabinoid receptors in brain: an in vitro technique using slide-mounted tissue sections. NIDA Res Monogr 112: 129-145.
23. Hilton J, Yokoi F, Dannals RF, Ravert HT, Szabo Z, Wong DF (2000). Column-switching HPLC for the analysis of plasma in PET imaging studies. Nuclear Med Biol 27: 627-630.
24. Horti AG, Fan H, Kuwabara H, Hilton J, Ravert HT, Holt DP et al (2006). 11C-JHU75528: a radiotracer for PET imaging of CB1 cannabinoid receptors. J Nucl Med 47: 1689-1696.
25. Howlett AC (2004). Efficacy in CB1 receptor-mediated signal transduction. Br J Pharmacol 142: 1209-1218.
26. Ichise M, Toyama H, Innis RB, Carson RE (2002). Strategies to improve neuroreceptor parameter estimation by linear regression analysis. J Cereb Blood Flow Metab 22: 1271-1281.
27. Innis RB, Cunningham VJ, Delforge J, Fujita M, Gjedde A, Gunn RN et al (2007). Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab 27: 1533-1539.
28. Kline RB (2010). Principles and Practice of Structural Equation Modeling. 3rd edn, The Guilford Press: New York.
29. LeDoux JE (2000). Emotion circuits in the brain. Annu Rev Neurosci 23: 155-184.
30. Lichtman AH, Hawkins EG, Griffin G, Cravatt BF (2002). Pharmacological activity of fatty acid amides is regulated, but not mediated, by fatty acid amide hydrolase in vivo. J Pharmacol Exp Ther 302: 73-79.
31. Lindstrom KM, Mandell DJ, Musa GJ, Britton JC, Sankin LS, Mogg K et al (2011). Attention orientation in parents exposed to the 9/11 terrorist attacks and their children. Psychiatry Res 187: 261-266.
32. Long JZ, Li W, Booker L, Burston JJ, Kinsey SG, Schlosburg JE et al (2009). Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects. Nat Chem Biol 5: 37-44.
33. Mackie K (2005). Distribution of cannabinoid receptors in the central and peripheral nervous system. Handb Exp Pharmacol 168: 299-325.
34. MacLeod C, Mathews A, Tata P (1986). Attentional bias in emotional disorders. J Abnorm Psychol 95: 15-20.
35. MacLeod C, Rutherford E, Campbell L, Ebsworthy G, Holker L (2002). Selective attention and emotional vulnerability: assessing the causal basis of their association through the experimental manipulation of attentional bias. J Abnorm Psychol 111: 107-123.
36. Malcher-Lopes R, Di S, Marcheselli VS, Weng FJ, Stuart CT, Bazan NG et al (2006). Opposing crosstalk between leptin and glucocorticoids rapidly modulates synaptic excitation via endocannabinoid release. J Neurosci 26: 6643-6650.
37. Marshall GN, Schell TL, Glynn SM, Shetty V (2006). The role of hyperarousal in the manifestation of posttraumatic psychological distress following injury. J Abnorm Psychol 115: 624-628.
38. Mechoulam R, Ben-Shabat S, Hanus L, Ligumsky M, Kaminski NE, Schatz AR et al (1995). Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 50: 83-90.
39. Melck D, Bisogno T, De Petrocellis L, Chuang H, Julius D, Bifulco M et al (1999). Unsaturated long-chain N-acyl-vanillylamides (N-AVAMs): vanilloid receptor ligands that inhibit anandamide-facilitated transport and bind to CB1 cannabinoid receptors. Biochem Biophys Res Commun 262: 275-284.
40. Neumeister A, Normandin MD, Murrough JW, Henry S, Bailey CR, Luckenbaugh DA et al (2012). Positron emission tomography shows elevated cannabinoid CB (1) receptor binding in men with alcohol dependence. Alcohol Clin Exp Res 36: 2104-2109.
41. Neumeister A, Normandin MD, Pietrzak RH, Piomelli D, Zheng MQ, Gujarro-Anton A et al (2013). Elevated brain cannabinoid CB1 receptor availability in post-traumatic stress disorder: a positron emission tomography study. Mol Psychiatry 18: 1034-1040.
42. Pietrzak RH, Feder A, Schechter CB, Singh R, Cancelmo L, Bromet EJ et al (2013). Dimensional structure and course of post-traumatic stress symptomatology in World Trade Center responders. Psycholog Med 44: 2085-2098.
43. Pietrzak RH, Goldstein MB, Malley JC, Rivers AJ, Southwick SM (2010). Structure of posttraumatic stress disorder symptoms and psychosocial functioning in Veterans of Operations Enduring Freedom and Iraqi Freedom. Psychiatry Res 178: 323-329.
44. Puente N, Cui Y, Lassalle O, Lafourcade M, Georges F, Venance L et al (2011). Polymodal activation of the endocannabinoid system in the extended amygdala. Nat Neurosci 14: 1542-1547.
45. Ramikie TS, Nyilas R, Bluett RJ, Gamble-George JC, Hartley ND, Mackie K et al (2014). Multiple mechanistically distinct modes of endocannabinoid mobilization at central amygdala glutamatergic synapses. Neuron 81: 1111-1125.
46. Rodrigues SM, Schafe GE, LeDoux JE (2004). Molecular mechanisms underlying emotional learning and memory in the lateral amygdala. Neuron 44: 75-91.
47. Rogan MT, Staubli UV, LeDoux JE (1997). Fear conditioning induces associative long-term potentiation in the amygdala. Nature 390: 604-607.
48. Ryberg E, Larsson N, Sjogren S, Hjorth S, Hermansson NO, Leonova J et al (2007). The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol 152: 1092-1101.
49. Salemink E, van den Hout MA, Kindt M (2007). Selective attention and threat: quick orienting versus slow disengagement and two versions of the dot probe task. Behav Res Therapy 45: 607-615.
50. Schell TL, Marshall GN, Jaycox LH (2004). All symptoms are not created equal: the prominent role of hyperarousal in the natural course of posttraumatic psychological distress. J Abnorm Psychol 113: 189-197.
51. Schlosburg JE, Blankman JL, Long JZ, Nomura DK, Pan B, Kinsey SG et al (2010). Chronic monoacylglycerol lipase blockade causes functional antagonism of the endocannabinoid system. Nat Neurosci 13: 1113-1119.
52. Sipe JC, Scott TM, Murray S, Harismendy O, Simon GM, Cravatt BF et al (2010). Biomarkers of endocannabinoid system activation in severe obesity. PLoS One 5: e8792.
53. Smart D, Gunthorpe MJ, Jerman JC, Nasir S, Gray J, Muir AI et al (2000). The endogenous lipid anandamide is a full agonist at the human vanilloid receptor (hVR1). Br J Pharmacol 129: 227-230.
54. Solomon Z, Horesh D, Ein-Dor T (2009). The longitudinal course of posttraumatic stress disorder symptom clusters among war veterans. J Clin Psychiatry 70: 837-843.
55. Sveen J, Dyster-Aas J, Willebrand M (2009). Attentional bias and symptoms of posttraumatic stress disorder one year after burn injury. J Nerv Ment Dis 197: 850-855.
56. Tsujikawa T, Zoghbi SS, Hong J, Donohue SR, Jenko KJ, Gladding RL et al (2014). In vitro and in vivo evaluation of (11)C-SD5024, a novel PET radioligand for human brain imaging of cannabinoid CB1 receptors. NeuroImage 84: 733-741.
57. Tzourio-Mazoyer N, Landeau B, Papathanassiou D, Crivello F, Etard O, Delcroix N et al (2002). Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. NeuroImage 15: 273-289.
58. Vellani V, Petrosino S, De Petrocellis L, Valenti M, Prandini M, Magherini PC et al (2008). Functional lipidomics. Calciumindependent activation of endocannabinoid/endovanilloid lipid signalling in sensory neurons by protein kinases C and A and thrombin. Neuropharmacology 55: 1274-1279.
59. Wang L, Zhang J, Shi Z, Zhou M, Li Z, Zhang K et al (2011). Comparing alternative factor models of PTSD symptoms across earthquake victims and violent riot witnesses in China: evidence for a five-factor model proposed by Elhai et al. (2011). J Anxiety Disord 25: 771-776.
60. Zoellner LA, Pruitt LD, Farach FJ, Jun JJ (2014). Understanding heterogeneity in PTSD: fear, dysphoria, and distress. Depress Anxiety 31: 97-106.
61. Zygmunt PM, Petersson J, Andersson DA, Chuang H, Sorgard M, Di Marzo V et al (1999). Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature 400: 452-457.